Document Detail

A randomized, double-blind, vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines.
MedLine Citation:
PMID:  19874316     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Solar lentigines are common, benign, cosmetically disfiguring lesions. Available physical treatments are effective, but they are costly and carry risks of side-effects.
OBJECTIVE: To evaluate the efficacy and safety of a preparation containing undecylenoyl phenylalanine 2% in the topical treatment of solar lentigines.
METHODS: In total, 36 patients with solar lentigines of the hands were randomly assigned to apply the active preparation on one side and the vehicle alone on the other side, twice daily for 12 weeks. Patients were evaluated monthly for efficacy and safety.
RESULTS: In all, 30 patients (28 women and 2 men; age range 47-75 years) completed the study. The duration of lesions ranged from 8 months to > 10 years. All patients responded partially on the side of the active treatment. Of the partial responders, 19 (63.3%) had moderate improvement and 11 (36.6%) had marked improvement. Improvement was evident from the first follow-up visit. On the side of the vehicle, 26 remained stable (86.6%) and 4 (13.3%) had partial improvement. There was a significant difference (P < 0.01) in efficacy of the active preparation vs. the vehicle. Using patient assessment ratings, 80% were 'much more satisfied/more satisfied' with the result. The reported side-effects were minor and included erythema and itching or burning on the side of active treatment.
CONCLUSIONS: Undecylenoyl phenylalanine 2% is a novel depigmenting agent, which possibly acts as an alpha-melanocyte-stimulating hormone antagonist, thus inhibiting melaninogenesis. It achieved a significant lightening of the lesions with minimal side-effects. Most patients were satisfied with the improvement. Undecylenoyl phenylalanine 2% may represent a safe, effective and inexpensive therapeutic alternative for solar lentigines.
A C Katoulis; A Alevizou; E Bozi; M Makris; A Zafeiraki; N Mantas; F Kousta; M Mistidou; A Kanelleas; N G Stavrianeas
Related Documents :
18201356 - A comparative study of different treatment frequencies of psoralen and ultraviolet a in...
22582226 - Shortcuts in arthroscopic knot tying: do they affect knot and loop security?
1873206 - The induction of epidermal ornithine decarboxylase following tape stripping is inhibite...
12207676 - Positive effect of using calcipotriol ointment with narrow-band ultraviolet b photother...
24154236 - Lobectomy in cystic fibrosis.
10616246 - Low-dose oral anticoagulation and antiplatelet therapy with st. jude medical heart valv...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-10-23
Journal Detail:
Title:  Clinical and experimental dermatology     Volume:  35     ISSN:  1365-2230     ISO Abbreviation:  Clin. Exp. Dermatol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-20     Completed Date:  2011-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7606847     Medline TA:  Clin Exp Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  473-6     Citation Subset:  IM    
Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, Attikon University General Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chi-Square Distribution
Dermatologic Agents / therapeutic use*
Double-Blind Method
Lentigo / drug therapy*
Middle Aged
Phenylalanine / analogs & derivatives*,  therapeutic use*
Sunlight / adverse effects
Treatment Outcome
alpha-MSH / antagonists & inhibitors*
Reg. No./Substance:
0/Dermatologic Agents; 581-05-5/alpha-MSH; 63-91-2/Phenylalanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  c-Ski promotes skin fibroblast proliferation but decreases type I collagen: implications for wound h...
Next Document:  Are dark-skinned people really protected from ultraviolet radiation?